TVTX Q4 2024 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+66.0% YoY

Gross Profit

$72M96.6% margin

Operating Income

-$61M-81.2% margin

Net Income

-$60M-80.6% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+18.9%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$45M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$594M

Total Liabilities

$535M

Stockholders' Equity

$59M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$45M	+66.0%
Gross Profit	$72M	$29M	+152.2%
Operating Income	-$61M	-$83M	+26.7%
Net Income	-$60M	-$90M	+33.2%

Revenue Segments

License

$1M100%